However, two cohort studies of men with clinically localised prostate cancer who did not undergo treatment (i.e. watchful waiting) showed that men who had TMPRSS2:ERG fusion had lower prostate cancer-specific survival compared to men without fusion expression (Attard et al, 2007; Demichelis et al, 2007). This evidence concerns the gene ERG and prostate cancer.